The clinical evaluation of use of Rizaben (Tranilast) in nasal allergies Optimum procedure for dose reduction and withdrawal

Abstract

Tranilast, inhibitor of mediator release, was administered to 163 cases of whole year nasal allergy for more than 8 weeks to examine its effectiveness and safety. From the 8th week on, dose reduction and withdrawal of Tranilast were under taken. Observations of exacerbation and/or relapse then continued for 13 weeks to find the optimum dose reduction and withdrawal procedures. On the basis of “Patients' impressions” 8 weeks after administration, dose reduction and withdrawal were set up. A part of “Very well”, administration was withdrawn. The other part of “Very well”, was reduced 3 to 1 capsule.“Well” or “Slightly well”, was reduced 3 to 2 capsules. Withdraw or reduce 3 to 1 capsule was determined randomly. The results of the overall estimation revealed a rate of effectiveness of 62.2 and 90.0% after 4 and 8 weeks, respectively. A rate of relapse following dose reduction and withdrawal was 25.0-33.3% without a difference in the rate of relapse according to dose reduction procedures. This suggests the necessary selection of a dose reduction procedure according to the degree of effectiveness of Tranilast.